In Brief: Bristol-Myers Squibb's Ovcon 35 withdrawal
Bristol-Myers Squibb's Ovcon 35 withdrawal: One lot of norethindrone and ethinyl estradiol oral contraceptive tablets voluntarily withdrawn by the company in recall announced Jan. 17. The lot recall involves about 150,000 compacts of blister packs of which a few compacts had weeks one and four (active ingredient vs. placebo) of the therapy transposed...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth